Insitro
Insitro raises $400M Series D at $2.8B valuation
Quick Facts
Insitro: Series D Funding Round
Insitro has successfully raised $400M in Series D funding, reaching a valuation of $2.8B.
Company Overview
Machine learning for drug discovery
Funding Details
The Series D round was led by Blackstone, with participation from Canada Pension Plan Investment Board, Arch Venture Partners, Foresite Capital, GV, Andreessen Horowitz.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2018
- Employees: 300+
- Category: Biotech
Investment
Insitro plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Blackstone: Verified investor in Series D
- Canada Pension Plan Investment Board: Verified investor in Series D
- Arch Venture Partners: Verified investor in Series D
- Foresite Capital: Verified investor in Series D
- GV: Verified investor in Series D
- Andreessen Horowitz: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...